Prevalencia del asma en escolares chilenos: estudio descriptivo de 24.470 niños: ISAAC-Chile / Prevalence of asthma in Chilean school age children: descriptive study in 24.470 children

Background: There is little information about the prevalence of asthma in Latin American children. Aim: To determine the prevalence of asthma among Chilean school age children. Subjects and methods: The prevalence of respiratory symptoms related to asthma in schoolchildren aged 7 and 13 years, coming from South Santiago, Central Santiago, Valdivia and Punta Arenas, was determined using the methodology of the International Study on Asthma and Allergies in Childhood (ISMC). A random sample of school children aged 6-7 and 13-14 years from each locality was selected. This resulted in 24)470 surveyed children (11,723 aged 6-7 years and 12,747 aged 13-14 years). Results: The current prevalence of wheezing ("wheezing in the last 12 months") ranged from 16.5 percent to 20.- percent in children aged 67 years, and from 6.8 percent to 11.7 percent in children aged 13-14 years. The cumulative prevalence of asthma ("asthma ever"), ranged from 9.7 percent and 16.5 percent in the 6-7 years group and from 7.3 percent to 12.4 percent in those aged 13-14 years. Conclusions: This study found much higher figures for prevalence of respiratory symptoms related to asthma in school children than those previously reported in this country, with a significant variability between centers (p<0.05). The prevalence of asthma in Chilean schoolchildren is as high and variable as that reported in industrialized countries

Enfermedad de Hodgkin en el niño: tratamiento combinado COPP modificado y radioterapia en estadios avanzados / Hodgkin's disease in children: modified COPP combined treatment and radiotherapy in advanced stages

Veintidós pacientes de la X Región menores de 15 años,con enfermedad de Hodgkin en estadios avanzados (8 III-A, 6 III-B y 8 IV-B), fueron tratados en el hospital de Valdivia en el decenio 1976-1985 con quimioterapia (esquema COPP modificado) y radioterapia. La sobrevida fue de 77,3% y la remisión completa mantida de 64,5% con un período de observación entre 3 y 13 años (mediana de observación 70 meses).Cinco pacientes fallecieron dentro de los dos primeros años y uno sofrió recidiva en el décimo año del seguimiento, pero volvió a presentar remisión completa. El tipo histológico depleción linfocitaria (5 casos) tuvo una sobrevida de 20,0%, mientras que la celularidad mixta (14 casos) tuvo una sobrevida de 92,9% (p = menor de 0,01). No se observaron en este grupo casos de segunda neoplasias atribuibles a la quimioterapia y radioterapia